Ra Capital Management, L.P. bought $6.9M of Parabilis Medicines (PBLS)
Executed Jul 20, disclosed Jul 22, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jul 22), the stock returned +38.7% (delay-adjusted); from the execution session (Jul 20), +26.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→21,188,750 sh across 2 lots
Exec Jun 11
Filed Jun 15 · 6:57 PM ET